Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose Radiotherapy and HDCT/Auto-SCT in CNS NGGCT
NCT02784054Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2014
- Primary completion
- Mar 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, etoposide, bleomycin, cyclophosphamide, thiotepa and 1 more in intracranial non-germinomatous germ cell tumor (NGGCT), sponsored by Samsung Medical Center. Primary endpoint: Event Free Survival at 3 years. Status: unknown.
02
Drugs
carboplatinetoposidebleomycincyclophosphamidethiotepa
03
Conditions
intracranial non-germinomatous germ cell tumor (NGGCT)
Beyond the preview
Go deeper on NCT02784054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784054.